PubMed Health⌕ Search

Biomedical subjects

S J Yawalkar

Publications and source records attributed to S J Yawalkar.

At least 19 recordsLinked to original sources
PubMed1991

Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis.

In two double-blind, parallel-group, multicenter trials, 0.05% halobetasol propionate cream was compared with 0.05% clobetasol 17-propionate cream and 0.05% betamethasone dipropionate cream in 264 patients with acute, severe exacerbations of atopic dermatitis. The efficacy of halobetasol propionate cream and betamethasone dipropionate cream was similar with regard to the success rate, as indicated by ratings of "healed" and "marked improvement" (88% versus 90%) and by an onset of therapeutic effect within 3 days of the start of treatment (40% versus 39%). The efficacy of halobetasol propionate cream and clobetasol 17-propionate cream was also similar with regard to success rates (89% versus 93%) and an onset of therapeutic effect within 3 days of the start of treatment (41% versus 38%). All three creams were well tolerated. Dryness of the skin and itching at the site of application were the reported adverse effects. Treatment was discontinued because of severe dryness of the skin in 1 of the 121 patients treated with halobetasol propionate cream and in 1 of the 59 patients treated with betamethasone dipropionate cream.

Administration, Cutaneous↗
PubMed1983

[Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate].

In a multicenter controlled study carried out in Austria and Switzerland by 8 dermatologists in 208 patients with acute eczematous dermatoses, 0.05% halometasone cream proved to have significantly superior clinical efficacy than 0.05% betamethasone dipropionate cream (P much less than 0.05) showing an equal tolerability. Good to very good results were reported in 93% of the patients treated with halometasone and in 84% of those treated with betamethasone dipropionate creams (Diprosone, Diproderm). General tolerability of both treatments was good. Neither skin atrophy nor any systemic adverse effect, due to the transcutaneous absorption of the corticoids, were observed in this study.

Administration, Topical↗
PubMed1983

An overview of international clinical trials with halometasone cream.

In international multicentre comparative clinical trials carried out by dermatologists in 717 patients with non-infected acute eczematous dermatoses at 28 trial centres in Austria, Germany, Holland, Switzerland and Yugoslavia, halometasone cream exhibited a very satisfactory therapeutic effect in acute contact dermatitis, atopic dermatitis, nummular dermatitis and seborrhoeic dermatitis. It yielded 'good' to 'very good' results in 89.7% of the 333 patients treated with halometasone cream. Halometasone cream was significantly more effective than Diproderm, Diprosone and Ultralan creams with respect to the overall success rate, the percentage of patients with 'very good' results and early cures. It proved marginally superior to Halciderm cream in therapeutic efficacy. The onset of therapeutic effect was more rapid in patients treated with halometasone cream than in those on treatment with comparative preparations. Halometasone cream was well tolerated and neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed. In view of the rapid onset of action, very good efficacy and tolerability, halometasone cream, with agreeable cosmetic and applicatory properties, may be considered as a suitable corticosteroid topical for the treatment of acute eczematous and other corticosteroid-responsive dermatoses.

Administration, Topical↗
PubMed1983

An overview of international clinical trials with halometasone ointment in chronic eczematous dermatoses.

Four international, multicentre, comparative clinical trials were carried out by twenty-two dermatologists in 569 patients with non-infected chronic eczematous dermatoses in Austria, Germany, Spain, Switzerland and Yugoslavia. In these clinical trials halometasone ointment exhibited a very satisfactory therapeutic effect in all the five types of non-infected chronic eczematous dermatitis, namely chronic contact dermatitis, atopic dermatitis, lichen simplex chronicus, seborrhoeic dermatitis and nummular dermatitis. It yielded an overall success rate ('good' to 'very good' results) of 85% as against 71% obtained with the comparative preparations. With regard to therapeutic effect, halometasone ointment proved significantly superior (p = 0.0001) to Ultralan ointment but it was less effective than Dermovate ointment (p = 0.052). It yielded overall success rates higher than those obtained with Diproderm (84.6% versus 74.4%) and Synalar (88.5% versus 72%) ointments. Halometasone ointment was well tolerated and neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed.

Administration, Topical↗
PubMed1983

Evaluation of halometasone ointment in the treatment of paediatric patients with chronic eczematous dermatoses.

Fifty children suffering from non-infected chronic eczematous dermatoses were treated with an ointment containing 0.05% halometasone, a new high potency trihalogenated synthetic corticosteroid. Halometasone ointment does not contain parabens or perfumes. The trial population consisted of patients (under 1 to 16 years old) with non-infected chronic nummular dermatitis, seborrhoeic dermatitis, atopic dermatitis and contact dermatitis. Halometasone ointment yielded very satisfactory therapeutic results and exhibited an excellent tolerability. It produced 'good' or 'very good' results in 82% of the patients and gave an overall cure rate of 76%. The number of patients obtaining an early cure, i.e. in less than 30 days, was thirty-six (72%). An early onset of therapeutic effect, i.e. within 6 days of starting the treatment, was reported in 77.1% of the patients. All the children (including eighteen infants) tolerated halometasone ointment well and no adverse effects, either due to local skin intolerability or the transcutaneous systemic absorption of the corticoid, were observed in this trial, nor were any instances of skin atrophy reported. Cosmetic acceptability and ease of application were considered 'good' in forty-nine (98%) patients.

Administration, Topical↗
PubMed1983

A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis.

A multicentre, between-patient, comparative trial was carried out by nine dermatologists in the Federal Republic of Germany to compare the efficacy and tolerability of 0.05 halometasone ointment with those of an ointment, containing 0.25% fluocortolone + 0.25% fluocortolone caproate, in patients with psoriasis vulgaris. The evaluable trial population consisted of 182 patients, 115 males and sixty-seven females. Halometasone ointment yielded a higher success rate ('good' to 'very good' results), namely 56.4% than that obtained with the comparative ointment (45.4%). Halometasone ointment also produced a higher cure rate, namely 26.6%, than that reported with the comparative preparation (19.3%). An improvement of one score over the pre-treatment clinical status of the psoriatic lesions reported at the Day 10 visit was significantly higher (p = 0.04), namely 48.9%, with halometasone ointment than that with the comparative preparation (35.2%). The percentages of patients obtaining an early cure, i.e. in less than 30 days, and onset of action were practically identical in both treatment groups. No adverse effects were reported in any of the ninety-four patients treated with halometasone ointment, while unwanted reactions were observed in three of the eighty-eight patients treated with the comparative preparation.

Administration, Topical↗
PubMed1983

Clinical evaluation on the long-term use of halometasone ointment in chronic eczema and psoriasis.

This clinical evaluation to determine the long-term therapeutic efficacy and tolerability of 0.05% halometasone ointment was carried out in fifty patients (forty-one with psoriasis and nine with chronic eczema) by seven dermatologists in Austria and Switzerland. The ages ranged from 19 to 76 years and the total duration of illness was more than 5 years in 62% of the trial population. The duration of treatment varied from 38 to 103 days (38-60 days in twenty-two patients, 61-90 days in twenty-five patients and 91-103 days in three patients). All patients received two non-occlusive applications of halometasone ointment per day. In this long-term study halometasone ointment exhibited very satisfactory therapeutic efficacy and very good tolerability. 'Good' to 'very good' results were reported in 73% and 89% of the patients with psoriasis and chronic eczema treated with halometasone ointment, respectively. Adverse effects were reported in only two (4%) patients who had transient itching at the site of application. Neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed in this study, nor were any instances of contact skin allergy reported.

Administration, Topical↗
PubMed1983

Evaluation of halometasone cream in the treatment of paediatric patients with acute eczematous dermatoses.

Sixty children under 10 years of age (including 18 under 3 years) suffering from non-infected acute eczematous dermatoses were treated with 0.05% halometasone cream containing a new high-potency trihalogenated synthetic dermatocorticosteroid. The trial population consisted of patients with acute atopic dermatitis, seborrhoeic dermatitis, nummular dermatitis and contact dermatitis. Halometasone cream yielded very satisfactory results and showed excellent tolerability. It produced 'good' or 'very good' results in 90% of the cases and gave an overall cure rate of 74.3%. The number of patients obtaining an early cure, i.e. in less than 20 days, was thirty-seven (62%). The onset of action was reported in 78.3% of the patients within 3 days of starting the treatment. All patients tolerated the treatment well and no adverse effects, either due to the topical application or the transcutaneous systemic absorption of the corticoid, were reported.

Acute Disease↗
PubMed1982

Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy.

In an international multicentre controlled single-blind trial of 93 previously untreated lepromatous leprosy patients the therapeutic effects of adding rifampicin, 450 mg/day orally or 1,200 mg once monthly in a single oral dose, to dapsone (50 mg/day orally) for the first 6 months of treatment were compared. Clinical and histopathological improvements and bacteriological regression, indicated by the decreases in the bacterial and morphological indices of the skin and nose-blow smears, were satisfactory and practically identical after 6 months' treatment. The once-monthly rifampicin schedule was better tolerated than the daily one. In view of the good therapeutic efficacy and tolerability, the much lower cost of treatment (about one-tenth of that of the daily rifampicin regimen) and the possibility of administration under supervision, once-monthly rifampicin given in a single oral 1,200 mg dose should be recommended, along with a standard dapsone regimen, for large-scale, initial, and intensive combination treatment of patients with lepromatous and borderline-lepromatous leprosy, to help prevent an increase in dapsone resistance. A third antileprosy drug (e.g., clofazimine) may be added to this initial dual-treatment regimen.

Adolescent↗
PubMed1982

A single application of crotamiton lotion in the treatment of patients with pediculosis capitis.

A single application of 10% crotamiton lotion cured 96% of the 49 patients treated for pediculosis capitis. Only two (4%) patients needed a second application. Following crotamiton application, pruritus regressed completely in 98% of the patients. An adverse effect, namely localized skin irritation leading to interruption of the trial treatment, was reported in one patient.

Administration, Topical↗
PubMed1981

A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.

In this controlled trial in 35 patients with lepromatous leprosy the therapeutic effects of adding rifampin 450 mg daily (Regimen A) or 1200 mg once a month (Regimen B) to a standard dapsone regimen of 50 mg daily were practically identical. Moderate to marked clinical improvement was observed in 88% and 83% of the patients treated with Regimens A and B respectively. The average rates of decrease in the MI of the skin smears and nose-blow smears were similar. The average decreases in the BI of the skin smears were 0.7 and 0.6 in patients on the Regimen A and B respectively. Following 6 months' treatment with Regimens A and B the average decreases in the Logarithmic Bacterial Indexes of Biopsies were 4.7% and 7% respectively. The once-monthly rifampin schedule was well tolerated and did not lead to "flu" syndrome, anuria, oliguria, hemolytic anemia, thrombocytopenia, or anaphylactic shock. This trial revealed the satisfactory efficacy, good tolerability, and practicability of a supervised once-monthly 1200 mg single oral dose rifampin schedule as a component of combination regimes for the initial treatment of patients with lepromatous (LLs and LLp) leprosy.

Adolescent↗
PubMed1979

Crotamiton cream and lotion in the treatment of infants and young children with scabies.

Fifty hospitalized infants and small children in the age-group of 3 months to 2 years admitted with scabies were treated with 5 applications of either 10% crotamiton cream or lotion on consecutive days. In this trial, the second to be performed exclusively in infants and young children, an improvement in itching was observed in all patients within 3 days of starting the treatment and the examination on Day 7 showed absence of skin lesions in all patients. Crotamiton cream as well as lotion rendered a 100% cure rate. All patients, including those having secondary pyoderma and/or eczematization tolerated the treatment with crotamiton cream and lotion well and no adverse reactions, either due to the topical application or to the transcutaneous systemic absorption of crotamiton, were reported. Post-treatment laboratory investigations did not reveal any unwanted effect due to transcutaneous systemic absorption of crotamiton on the blood, kidneys or liver. Crotamiton is the only scabicide available today which displays not only antiprurtic but also marked antibacterial properties. It is especially indicated in the treatment of scabies in children as they are very prone to secondary bacterial infection following scratching. In view of its good efficacy and excellent tolerability the 5-application treatment schedule, with crotamiton cream applied to the whole body from the chin downward, can therefore be recommended as an optimum form of treatment for scabies in infants and young children.

Administration, Topical↗